CSIMarket
 


Fibrogen Inc   (NASDAQ: FGEN)
Other Ticker:  
 
 

FGEN's Revenue Growth by Quarter and Year

Fibrogen Inc 's Revenue results by quarter and year

 



FGEN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December - 0.00 27.14 34.37
3rd Quarter September - 46.33 40.13 15.74
2nd Quarter June - 50.64 44.32 29.81
1st Quarter March 2.74 55.90 36.16 60.83
FY   2.74 152.87 147.75 140.75

FGENs Annual Revenue
Fibrogen Inc 's Revenue in the fiscal year 2024 $ 29.62 millions
Fibrogen Inc 's Revenue in the fiscal year 2023 $ 147.75 millions
Fibrogen Inc 's Revenue in the fiscal year 2022 $ 140.73 millions
Fibrogen Inc 's Revenue in the fiscal year 2021 $ 235.31 millions
Fibrogen Inc 's Revenue in the fiscal year 2019 $ 256.58 millions




FGEN Revenue first quarter 2025 Y/Y Growth Comment
Fibrogen Inc reported drop in Revenue in the first quarter 2025 by -95.1% to $ 2.74 millions, from the same quarter in 2024.
The fall in the first quarter 2025 Fibrogen Inc 's Revenue compares unfavorably to the Company's average Revenue increase of 15.38%.

Looking into first quarter 2025 results within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue growth. While Fibrogen Inc ' s Revenue meltdown of -95.1% ranks overall at the positon no. 640 in the first quarter 2025.




FGEN Revenue ( Y/Y Growth %) 2025
2024 2023 2022
4th Quarter December - - -21.04 % 107.8 %
3rd Quarter September - 15.45 % 154.96 % -89.91 %
2nd Quarter June - 14.26 % 48.67 % 22.37 %
1st Quarter March -95.1 % 54.59 % -40.56 % 58.29 %
FY   - 3.47 % 4.97 % -40.18 %

Financial Statements
Fibrogen Inc 's first quarter 2025 Revenue $ 2.74 millions FGEN's Income Statement
Fibrogen Inc 's first quarter 2024 Revenue $ 55.90 millions Quarterly FGEN's Income Statement


FGEN Revenue (Quarter on Quarter Growth %)

2025
2024 2023 2022
4th Quarter December - - -32.37 % 118.36 %
3rd Quarter September - -8.51 % -9.45 % -47.2 %
2nd Quarter June - -9.41 % 22.57 % -50.99 %
1st Quarter March - 105.97 % 5.21 % 267.78 %
FY (Year on Year)   - 3.47 % 4.97 % -40.18 %




Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #155
Overall #640

Revenue Y/Y Growth Statistics
High Average Low
142.35 % 15.38 % -69.24 %
(Sep 30 2021)   (Jun 30 2020)
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #67
Healthcare Sector #155
Overall #640
Revenue Y/Y Growth Statistics
High Average Low
142.35 % 15.38 % -69.24 %
(Sep 30 2021)   (Jun 30 2020)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Fibrogen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


FGEN's I. Quarter Q/Q Revenue Comment


Fibrogen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)
12 Months Ending
(Dec 31 2024)
12 Months Ending
(Sep 30 2024)
12 Months Ending
(Jun 30 2024)
12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 180.01 $ 173.82 $ 167.49
Y / Y Revenue Growth (TTM) - - 16.15 % 33.11 % 44.31 %
Year on Year Revenue Growth Overall Ranking # 227 # 1580 # 365 # 3416 # 0
Seqeuential Revenue Change (TTM) - - 3.57 % 3.77 % 13.36 %
Seq. Revenue Growth (TTM) Overall Ranking # 808 # 2570 # 630 # 930 # 0


Cumulative Revenue growth Comment
Fibrogen Inc realized trailing twelve months of $ 0 millions, in the Mar 31 2025, compare to Revenue of $ 167 millions a year ago.

In the Healthcare sector 64 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 227, from total ranking in previous quarter at 1580.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 65
Overall # 227

Revenue TTM Y/Y Growth Statistics
High Average Low
142.35 %
15.38 %
-69.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 180
S&P 500 # 808
Cumulative Revenue growth Comment
Fibrogen Inc realized trailing twelve months of $ 0 millions, in the Mar 31 2025, compare to Revenue of $ 167 millions a year ago.

In the Healthcare sector 64 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 227, from total ranking in previous quarter at 1580.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 73
Healthcare Sector # 65
Overall # 227

Revenue TTM Y/Y Growth Statistics
High Average Low
142.35 %
15.38 %
-69.24 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 73
Sector # 180
S&P 500 # 808




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
FGEN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for FGEN's Competitors
Revenue Growth for Fibrogen Inc 's Suppliers
Revenue Growth for FGEN's Customers

You may also want to know
FGEN's Annual Growth Rates FGEN's Profitability Ratios FGEN's Asset Turnover Ratio FGEN's Dividend Growth
FGEN's Roe FGEN's Valuation Ratios FGEN's Financial Strength Ratios FGEN's Dividend Payout Ratio
FGEN's Roa FGEN's Inventory Turnover Ratio FGEN's Growth Rates FGEN's Dividend Comparisons



Companies with similar Revenue meltdown for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Carlisle Companies Incorporated-0.06%$ -0.064 millions
Henry Schein Inc -0.13%$ -0.126 millions
Tactile Systems Technology Inc -0.14%$ -0.137 millions
Alpha Pro Tech Ltd -0.19%$ -0.186 millions
Gilead Sciences Inc -0.28%$ -0.284 millions
Jazz Pharmaceuticals Plc-0.46%$ -0.459 millions
Milestone Scientific Inc -0.73%$ -0.730 millions
Logicmark Inc-0.74%$ -0.738 millions
Yunhong Green Cti Ltd -0.74%$ -0.745 millions
Amphastar Pharmaceuticals Inc -0.76%$ -0.761 millions
Enhabit Inc -0.95%$ -0.953 millions
Elanco Animal Health Incorporated-1.00%$ -0.996 millions
Envista Holdings Corporation-1.17%$ -1.171 millions
Globus Medical Inc -1.41%$ -1.409 millions
Merck and Co Inc -1.56%$ -1.559 millions
Icad Inc-1.61%$ -1.615 millions
Fortrea Holdings Inc -1.63%$ -1.631 millions
Align Technology inc -1.78%$ -1.776 millions
Adapthealth Corp -1.84%$ -1.844 millions
Sunlink Health Systems Inc -2.05%$ -2.050 millions
Tonix Pharmaceuticals Holding Corp -2.14%$ -2.135 millions
Alpha Teknova Inc -2.19%$ -2.194 millions
Quidelortho Corp-2.56%$ -2.560 millions
Teladoc Health Inc -2.59%$ -2.594 millions
Tenet Healthcare Corp-2.70%$ -2.701 millions
Charles River Laboratories International inc -2.71%$ -2.708 millions
Scientific Industries Inc -3.10%$ -3.100 millions
Caribou Biosciences Inc -3.13%$ -3.129 millions
Apellis Pharmaceuticals Inc -3.21%$ -3.208 millions
Illumina Inc -3.25%$ -3.253 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com